Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

352
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
352
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

172
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
172
Allergic Reactions02:06

Allergic Reactions

33.6K
Overview
33.6K
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Antibody Structure01:10

Antibody Structure

67.5K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
67.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine.

Frontiers in immunology·2026
Same author

Targeting the neutrophil-DPP-1-protease axis in airway disease: current evidence and future indications.

Respiratory medicine·2026
Same author

Allergen Immunotherapy and Possible Clinical Remission: Toward a Disease-Modifying Paradigm in Allergic Disorders.

Biomedicines·2026
Same author

Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort.

Journal of personalized medicine·2026
Same author

Vascular remodeling in asthma: from mechanisms to precision medicine.

Current opinion in allergy and clinical immunology·2026
Same author

Use of an Anti-Thymic Stromal Lymphopoietin Agent in Patients With Asthma and Clinically Significant Bronchiectasis: A Case Series.

Chest·2026
Same journal

Biosimilars in allergology: an outline in pediatric patients.

Current opinion in allergy and clinical immunology·2026
Same journal

The immunogenetic landscape of systemic lupus erythematosus.

Current opinion in allergy and clinical immunology·2026
Same journal

Circadian control of innate immunity: molecular mechanisms and implications for allergic disorders.

Current opinion in allergy and clinical immunology·2026
Same journal

Probiotics in allergic disease: from adjunct supplement to immune-modifying strategy (2026 update).

Current opinion in allergy and clinical immunology·2026
Same journal

Updates on drug-induced anaphylaxis in children.

Current opinion in allergy and clinical immunology·2026
Same journal

Beta-lactam de-labelling as a core antimicrobial stewardship strategy in the era of the antimicrobial resistance pandemic: a narrative review.

Current opinion in allergy and clinical immunology·2026
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.1K

Biosimilars in allergic diseases.

Matteo Ferrando1, Diego Bagnasco, Fulvio Braido

  • 1aDIMI Department of Internal Medicine, Allergy and Respiratory Diseases, University of Genoa, IRCCS AOU San Martino-IST, Genoa bDepartment of Translational Medical Sciences, Division of Clinical Immunology and Allergy, University of Naples Federico II, Napels, Italy.

Current Opinion in Allergy and Clinical Immunology
|November 24, 2015
PubMed
Summary
This summary is machine-generated.

Biological and biosimilar drugs offer new hope for treating allergic and immunologic diseases. As patents expire, biosimilars promise to lower costs and improve patient access to these advanced therapies.

More Related Videos

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

17.0K
Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.8K

Related Experiment Videos

Last Updated: Mar 29, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.1K
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

17.0K
Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.8K

Area of Science:

  • Immunology
  • Pharmacology
  • Health Economics

Background:

  • Review of historical and current asthma treatment strategies.
  • Focus on biological therapies for allergic and immunologic diseases.
  • Examination of the economic implications of these treatments.

Purpose of the Study:

  • To provide an overview of biological and biosimilar drugs in treating allergic and immunologic diseases.
  • To discuss the evolution of asthma treatment and current biological therapies.
  • To analyze the economic perspective of these advanced treatments.

Main Methods:

  • Literature review of biological and biosimilar drug treatments.
  • Analysis of current approved therapies and premarketing studies.
  • Economic evaluation of healthcare system sustainability.

Main Results:

  • Omalizumab is the only approved biological therapy for allergic diseases currently.
  • Several monoclonal antibodies are in development, but high costs pose challenges for healthcare systems.
  • The high cost of current biological therapies limits patient accessibility.

Conclusions:

  • Patent expirations for biological treatments will pave the way for biosimilars.
  • Biosimilars are expected to reduce healthcare costs.
  • Increased accessibility to previously unaffordable therapies for patients is anticipated.